Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Merck & Co
(NY:
MRK
)
131.20
+0.48 (+0.37%)
Official Closing Price
Updated: 7:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Merck & Co
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
16
17
Next >
LYNPARZA® (olaparib) Approved in Japan as Adjuvant Treatment for Patients With BRCA-Mutated, HER2-Negative High Recurrent Risk Breast Cancer
August 25, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck Receives Fast Track Designation from the U.S. FDA for MK-2060, an Investigational Anticoagulant Therapy
August 23, 2022
From
Merck & Co., Inc.
Via
Business Wire
FDA Accepts Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone for Patients With Metastatic Castration-Resistant Prostate Cancer and Grants Priority Review
August 16, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck and Orna Therapeutics Collaborate to Advance Orna’s Next Generation of RNA Technology
August 16, 2022
From
Merck & Co., Inc.
Via
Business Wire
NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) Pioneering Innovative Hypertension Treatments
August 11, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
The Power of Science to Stop a Killer
August 08, 2022
Via
Investor Brand Network
The Power of Science to Stop a Killer
August 08, 2022
NetworkNewsWire Editorial Coverage New York, NY – August 8, 2022 – Nearly half of all American adults suffer from hypertension (high blood pressure), often referred to as a silent killer. More than 114...
Via
FinancialNewsMedia
LYNPARZA® (olaparib) Approved in the EU as Adjuvant Treatment for Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer
August 04, 2022
From
Merck & Co., Inc.
Via
Business Wire
3 Pharma Stocks' Post-Earnings Price Moves
August 04, 2022
The health care sector is participating in the S&P's nascent rally, but pharmaceuticals AbbVie, Merck and Pfizer are holding up well relative to the market.
Via
MarketBeat
Topics
ETFs
Stocks
Exposures
US Equities
Merck and Eisai Provide Update on Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
August 03, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck Provides Update on Phase 3 KEYNOTE-921 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
August 03, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Second-Quarter 2022 Financial Results
July 28, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Fourth-Quarter 2022 Dividend
July 26, 2022
From
Merck & Co., Inc.
Via
Business Wire
Three Watchlist Stocks to Capitalize on Sector Rotation
July 23, 2022
Sector rotation is a common market event based on the theory that economies move in cycles. Here are three stocks, one apiece, from sectors that institutions are rotating into.
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
Merck Provides Update on Phase 3 KEYNOTE-412 Trial in Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma
July 20, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck and Orion Announce Global Collaboration for the Development and Commercialization of ODM-208, an Investigational Steroid Synthesis Inhibitor for the Treatment of Metastatic Castration-Resistant Prostate Cancer
July 13, 2022
From
Merck & Co., Inc.
Via
Business Wire
Is Merck & Co. Inc. (NYSE: MRK) a Great Long-Term Dividend Pick?
July 12, 2022
When you're on the hunt for a great long-term dividend stock, you may want the perfect stock. The Dividend Aristocrats or Dividend Kings may come to mind first — companies that have proven they offer a...
Via
MarketBeat
Merck Announces the Launch of the Merck Digital Sciences Studio to Help Healthcare Startups Quickly Bring their Innovations to Market
June 29, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck to Hold Second-Quarter 2022 Sales and Earnings Conference Call July 28
June 29, 2022
From
Merck & Co., Inc.
Via
Business Wire
LYNPARZA® (olaparib) Receives Positive Opinion From EU CHMP as Adjuvant Treatment for Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer
June 27, 2022
From
Merck & Co., Inc.
Via
Business Wire
European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent Patients (≥12 Years of Age) With Stage IIB or IIC Melanoma Following Complete Resection
June 24, 2022
From
Merck & Co., Inc.
Via
Business Wire
CDC’s ACIP Unanimously Votes to Provisionally Recommend Use of Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) as an Option for Pneumococcal Vaccination in Infants and Children
June 22, 2022
From
Merck & Co., Inc.
Via
Business Wire
U.S. FDA Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Infants and Children
June 22, 2022
From
Merck & Co., Inc.
Via
Business Wire
Results From Phase 3 PROpel Trial of LYNPARZA® (olaparib) Plus Abiraterone in First-Line Metastatic Castration-Resistant Prostate Cancer Published in NEJM Evidence
June 21, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces that Chirfi Guindo will Lead Marketing for Merck Human Health
June 21, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tackling Recurring Health Conditions Offers Hope to Patients
June 21, 2022
Palm Beach, FL – June 21, 2022 – FinancialNewsMedia.com News Commentary – Being diagnosed with a health condition can often come as a shock but finding out it can recur is a double blow, particularly...
Via
FinancialNewsMedia
Merck Presents Positive Results from Phase 1/2 Study Evaluating V116, the Company’s Investigational Pneumococcal Conjugate Vaccine for Adults
June 21, 2022
From
Merck & Co., Inc.
Via
Business Wire
FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Stage IB (≥4 centimeters)-IIIA Non-Small Cell Lung Cancer Following Complete Surgical Resection
June 13, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck to Participate in the 2022 Goldman Sachs 43rd Annual Global Healthcare Conference
June 08, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck and Ridgeback Announce New Data For Investigational LAGEVRIO™ (molnupiravir) From Phase 3 MOVe-OUT Study
June 07, 2022
From
Merck & Co., Inc.
Via
Business Wire
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.